3 research outputs found

    Efficacy and safety of pharmacological treatment of the with clinically apparent bacteriuria and asymptomatic bacteriuria in the pregnant women

    Get PDF
    The article explores the problem of urinary tract infection in pregnant women. It presents the statistical analysis of the frequency of different forms of urinary tract infection during pregnancy. Our data is compared to the statistics given by other national and international researcher

    Efficacy and safety of pharmacological treatment of the with clinically apparent bacteriuria and asymptomatic bacteriuria in the pregnant women

    No full text
    The article explores the problem of urinary tract infection in pregnant women. It presents the statistical analysis of the frequency of different forms of urinary tract infection during pregnancy. Our data is compared to the statistics given by other national and international researcher

    Post-finasteride syndrome: our current knowledge

    Get PDF
    5-α reductase inhibitors are effective and commonly used medications for the treatment of benign prostatic hyperplasia. However, there are some questions about the safety of such medications. A post-finasteride syndrome is a controversial syndrome associated with a constellation of sexual, physical, and psychological symptoms that develop during or after finasteride exposure and persist after discontinuation. Finasteride and dutasteride have the same mechanism of action and we can suppose that the term «post-finasteride syndrome» may apply to the whole group of 5-alfa reductase inhibitors. Nowadays, reasons and development mechanisms of this syndrome are unclear. The results of studies on sexual, physical, and psychological disorders have shown mixed results. Some experts attribute post-finasteride syndrome to a group of «mysterious diseases» based on psychosocial factors. Also, we need new studies with better design because reasons and development mechanisms of this syndrome are unclear.Aleksandr A. Galushkin and Dmitriу G. Likhikh are employees GlaxoSmithKline Trading, Michael I. Kogan declares no conflict of interest
    corecore